A network pharmacology-based investigation of emodin against pancreatic adenocarcinoma.

Xueying Shi, Bingqian Huang, Jingyi Zhu, Takuji Yamaguchi, Ailing Hu, Masahiro Tabuchi, Daisuke Watanabe, Seiichiro Yoshikawa, Shinobu Mizushima, Akio Mizushima, Shilin Xia

Medicine 2023 May 19

filter terms:

Pancreatic adenocarcinoma (PAAD) is one of the most common malignancies worldwide with an increasing incidence and poor outcome due to the lack of effective diagnostic and treatment methods. Emerging evidence implicates that emodin displays extensive spectrum anticancer properties. Differential expression genes in PAAD patients were analyzed by Gene Expression Profiling Interactive Analysis (GEPIA) website, and the targets of emodin were obtained via Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform. Subsequently, enrichment analyses were performed using R software. A protein-protein interaction (PPI) network was constructed by STRING database and Cytoscape software was used to identify the hub genes. Prognostic value and immune infiltration landscapes were explored through Kaplan-Meier plotter (KM plotter) website and the Single-Sample Gene Set Enrichment Analysis package of R. Finally, molecular docking was used to computationally verify the interaction of ligand and receptor proteins. A total of 9191 genes were significantly differentially expressed in PAAD patients and 34 potential targets of emodin were obtained. Intersections of the 2 groups were considered as potential targets of emodin against PAAD. Functional enrichment analyses illustrated that these potential targets were linked to numerous pathological processes. Hub genes identified through PPI networks were correlated with poor prognosis and infiltration level of different immune cells in PAAD patients. Perhaps emodin interacted with the key molecules and regulate the activity of them. We revealed the inherent mechanism of emodin against PAAD with the aid of network pharmacology, which provided reliable evidence and a novel guideline for clinical treatment. Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

Citation

Xueying Shi, Bingqian Huang, Jingyi Zhu, Takuji Yamaguchi, Ailing Hu, Masahiro Tabuchi, Daisuke Watanabe, Seiichiro Yoshikawa, Shinobu Mizushima, Akio Mizushima, Shilin Xia. A network pharmacology-based investigation of emodin against pancreatic adenocarcinoma. Medicine. 2023 May 19;102(20):e33521